The US Food and Drug Administration offered treats and probably a little bit of a scare to COVID vaccine sponsors on the Friday before Halloween when it gave Pfizer Inc. emergency use authorization for its COVID-19 vaccine in children 5-11 and then apparently told Moderna, Inc. that safety concerns would extend the review of its vaccine for use in 12- to 17-year-olds.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?